Oxford BioDynamics PLC OBD enters into master service agreement (5578X)
20 Dicembre 2019 - 8:00AM
UK Regulatory
TIDMOBD
RNS Number : 5578X
Oxford BioDynamics PLC
20 December 2019
20 December 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics enters into master service agreement with
world leading US pharmaceutical company to evaluate EpiSwitch(TM)
biomarkers
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
focused on the discovery and development of biomarkers, based on
regulatory 3D genome architecture, for use within the
pharmaceutical and biotechnology industry, is pleased to announce
that it has entered into a master service agreement for the
development of predictive EpiSwitch(TM) biomarkers with a top US
pharmaceutical company.
This agreement builds on OBD's proven ability to develop
predictive biomarkers for response in immuno-oncology, as presented
at The Society for Immunotherapy of Cancer's (SITC) 34th Annual
Meeting in November this year.
Under the terms of the master service agreement, the US
pharmaceutical company will be granted access to OBD's unique
EpiSwitch(TM) technology for use in the development of predictive
biomarkers. Details of the agreement and financial terms are not
disclosed.
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, said:
"We are delighted to have entered into this new agreement with a
major US pharmaceutical company, built on the success of our prior
predictive biomarker development and validation. We are pleased to
be delivering robust biomarkers of high value to our clients, as
part of our commercial presence in the US, and are excited to
further demonstrate the value of EpiSwitch(TM) patient
stratification, with all the potential it holds for drug
development and personalized patient care."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
Edward Mansfield
John More +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations
Adviser
Natalie Garland-Collins
Mary Whittow
Alex Shaw +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGGGAUPUPBGMB
(END) Dow Jones Newswires
December 20, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Oxford Biodynamics (LSE:OBD)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxford Biodynamics (LSE:OBD)
Storico
Da Apr 2023 a Apr 2024